Business
Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board
BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors. These leadership appointments reflect a pivotal moment for Clairity following FDA De Novo authorization
About this update from Masimo Corporation
[{"type":"text","content":"BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors.","length":395,"tagName":"p"},{"type":"text","content":"These leadership appointments reflect a pivotal moment for Clairity following FDA De Novo authorization of its mammography-based AI risk prediction platform and increasing engagement with health systems and partners worldwide.","length":226,"tagName":"p"},{"type":"text","content":"Clairity’s innovation aligns with national priorities to improve health outcomes, strengthen early disease prevention, reduce avoidable health care costs, and advance the responsible application of medical artificial intelligence. As the company scales deployment across the United States, Clairity is actively engaging with public- and private-sector stakeholders while maintaining a long-term global vision.","length":409,"tagName":"p"},{"type":"text","content":"As CEO, Dr. Lehman will lead company strategy, operations, and partnerships as Clairity integrates across a global and diverse range of clinical environments.","length":158,"tagName":"p"},{"type":"text","content":"“Clairity is at a defining moment,” said Joe Kiani, Chairman of the Clairity Board, Founder of the global medical technology company Masimo (NASDAQ: MASI), and Founder and Executive Chairman of Willow Laboratories. “With FDA De Novo authorization and growing demand from health systems, the company is uniquely positioned to lead the next era of breast cancer screening and prevention through its risk prediction platform. Connie is the visionary founder behind this technology and the right leader to guide Clairity forward as we scale impact and expand access to truly personalized risk assessment.”","length":601,"tagName":"p"},{"type":"text","content":"“For decades, breast cancer care has been anchored in detection and diagnosis, intervening only after disease has already developed,” said Dr. Lehman. “While early detection saves lives, we can and must do better to identify risk earlier, personalize screening, and shift the paradigm toward preventio...